Table 1.
Non-severe COVID-19 patients baseline characteristics and 6-week follow-up
| Baseline (n = 311) | |
|---|---|
| Age, years | 39 [29–51] |
| Female sex | 187 (60.1%) |
| At least one comorbidity | 61 (19.6%) |
| Active smoking | 25 (8.0%) |
| Chronic respiratory disease | 25 (8.0%) |
| Chronic heart disease | 14 (4.5%) |
| Six-week health status (n = 214) | |
| Returned to baseline health status, no residual symptom | 115 (53.7%) |
| Dyspnea | 86 (40.2%) |
| - Only on exertion | 76 (35.6%) |
| - Permanent | 10 (4.7%) |
| Cough | 41 (19.2%) |
| Chest pain | 23 (10.7%) |
| Weight loss | 83 (38.8%) |
| Sleep disorders | 68 (31.8%) |
| Anxiety | 56 (26.2%) |
| Sadness | 27 (12.6%) |
| Respiratory functional explorations (n = 23) | |
| Decreased DLCO | 9/23 (39%) |
| Clinical bronchial hyper-reactivity | 7/23 (30%) |
| Restrictive syndrome | 1/23 (4%) |
| Obstructive syndrome | 0/23 (0%) |
| Chest CT scan findings (n = 23) | |
| Ground glass lesions* | 4 (17%) |
| Pulmonary fibrosis | 0 |
Quantitative data are reported as median [interquartile range] and qualitative data as number (%)
DLCO diffusing capacity of the lung for carbon monoxide
*In all cases (4/4), lesions were significantly improved as compared to baseline CT scan